Carfilzomib superior to bortezomib for relapsed multiple. Carfilzomib is administered as a 210minute infusion on days 1, 2, 8, 9, 15, and 16 of a 28day cycle at a starting dose of 20 mgm 2 for cycle 1 and a target dose of 27 mgm 2 thereafter. May 02, 2019 the phase 3 clarion study compared carfilzomib melphalanprednisone kmp with bortezomibmelphalanprednisone vmp in transplantineligible newly diagnosed multiple myeloma ndmm patients. Does carfilzomib offer advantages to currently available alternatives. Carfilzomib rituximab desensitization in sensitized heart transplant candidates. Carfilzomib can partially overcome resistance in bortezomibrefractory patients and has significant efficacy in bortezomibnaive patients. In animals, carfilzomib inhibited proteasome activity in blood and tissue and delayed tumor growth in models of multiple myeloma, hematologic, and solid tumors. If patient starting dose was 10 mg daily, resume at 5 mg less than previous dose. Carfilzomib kyprolis for multiple myeloma chemoexperts.
The attached package contains background information prepared by the food and drug administration fda for the panel members of the advisory committee. An individually packaged singledose vial containing 10 mg of carfilzomib as a white to offwhite lyophilized cake or powder. Eximpulse services will provide you the latest and relevant market intelligence reports of carfilzomib import data. Kyprolis carfilzomib is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy kyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of. Carfilzomib marketed under the trade name kyprolis, developed by onyx pharmaceuticals is an anticancer drug acting as a selective proteasome inhibitor. Administration infuse over 10 or 30 minutes depending on the kyprolis dose regimen see dosage and administration 2. Final page is signature page and is kept on file, but not issued with policy. Darzalex is a cd38directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma 1. Kyprolis 56 mgm 2 is infused intravenously over 30 minutes. Does carfilzomib offer advantages over current vanf agents. What do i need to tell my doctor before i take carfilzomib. Highlightsof prescribing information kyprolis safely and. Kyprolis carfilzomib is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib a consensus paper by the european myeloma.
Kyprolis carfilzomib is a treatment option for people who have already received 1 or more previous treatments for relapsed multiple myeloma. Randomized, openlabel, phase 3 study in subjects with relapsed and refractory multiple myeloma receiving carfilzomib in combination with dexamethasone, comparing onceweekly versus twiceweekly carfilzomib dosing trial evaluated approximately 478 patients with relapsed and refractory multiple myeloma who have received at least. Kyprolis carfilzomib for injection, for intravenous use initial u. Carfilzomib is in a class of medications called proteasome inhibitors. Highlightsof prescribing information these highlights do not include all the information needed to use kyprolis safely and effectively. Thrombocytopenia has been reported with ninlaro with platelet nadirs typically occurring between days 1421 of each 28day cycle and recovery to baseline by the start of the next cycle. Pdf carfilzomibrituximab desensitization in sensitized. Fda approves new kyprolis carfilzomib combination therapy for. Carfilzomib injection is used alone and in combination with dexamethasone or lenalidomide revlimid and dexamethasone to treat people with multiple myeloma a type of cancer of the bone marrow who have already been treated with other medications. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin. Carfilzomib or bortezomib with melphalanprednisone for. It is sometimes given with other medicines when treating relapsed multiple myeloma. Return to at least 1,000mcl if patient starting dose was 20 mg daily, resume revlimid at 5 mg less than the previous dose. Kyprolis carfilzomib in combination with lowdose dexamethasone is superior to velcade bortezomib plus lowdose dexamethasone for.
Fda briefing document oncologic drugs advisory committee. Highlights of prescribing information these highlights do not include all the information needed to use revlimid safely and effectively. Administration kyprolis can be administered in a 50ml or 100ml intravenous bag of 5% dextrose injection, usp. Infuse over 10 or 30minutes depending on the kyprolis dose regimen see dosage and administration 2. Dbodfs that is not known to most patients at the time of diagnosis. Caution should be used in calculating the quantity delivered to prevent overdosing. It is used with lenalidomide and dexamethasone in patients whose disease has recurred come back or is refractory does not respond to treatment and who have already received one to three other types of treatment. Dec 04, 2019 a study showed that these patients taking carfilzomib with certain other drugs melphalan and prednisone had more very bad and sometimes deadly side effects compared to a certain other drug. Multiple myeloma disease trajectory kyprolis carfilzomib. Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds to the nterminal threoninecontaining active sites of the 20s proteasome, the proteolytic core particle within the 26s proteasome. For additional information please refer to the bortezomib and dexamethasone prescribing information. In combination with the medicines lenalidomide and dexamethasone in people with newly diagnosed multiple myeloma who cannot receive a type of stem cell transplant that uses their own stem cells autologous stem cell transplant and in people who have received at least one prior medicine to treat multiple myeloma. Kyprolis 27 mgm 2 is infused intravenously for 10 minutes. Sep 28, 2012 carfilzomib is a secondgeneration proteasome inhibitor with welldocumented clinical activity as a single agent in patients with relapsedrefractory multiple myeloma.
Prior to each dose in cycle 1, give 250 ml to 500 ml of intravenous normal saline or other appropriate. Daratumumab plus carfilzomib and dexamethasone in patients. Carfilzomib is a proteasome inhibitor that binds to rapidly dividing plasma cells and causes cell death. Oct 01, 2019 kyprolis carfilzomib is a cancer medicine that interferes with the growth and spread of cancer cells in the body. If you have an allergy to carfilzomib or any other part of carfilzomib. You can use this carfilzomib import data for multiple kinds of analysis. Oct 04, 2019 carfilzomib is a crystalline substance with a molecular weight of 719. Carfilzomib is practically insoluble in water and very slightly soluble in acidic conditions. Carfilzomibdexamethasone vs bortezomibdexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study endeavor. Carfilzomib kyprolis carfilzomib kyprolis is a chemotherapy regimen for multiple myeloma mm how does carfilzomib work. Carfilzomib is associated with a low rate of serum enzyme elevations during treatment and has been implicated to rare instances of clinically apparent, acute liver injury some of which have been fatal. Independent, uptodate news and information for the multiple myeloma community. Carfilzomib is approved to be used alone or with other drugs to treat. Fda approves new kyprolis carfilzomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma pivotal headtohead endeavor study shows kyprolis and dexamethasone doubled progressionfree survival versus velcade bortezomib and dexamethasone.
Kyprolis carfilzomib dosing, indications, interactions. An individually packaged singledose vial containing 30 mg of carfilzomib as a white to offwhite lyophilized cake or powder. Management of adverse drug reactions may require treatment interruption andor dose reductions. The quantity of kyprolis carfilzomib contained in one singledose vial 30 mg or 60 mg may exceed the recommended dose. Do not mix with or administer as an infusion with other medicinal products. These highlights do not include all the information needed to use fibryna safely and effectively. Kyprolis carfilzomib is a prescription medication used to treat patients with relapsed or refractory multiple myeloma who have received one to three previous treatments for multiple myeloma. Store in accordance with information listed on the product insert. These highlights do not include all the information needed to use advate safely and effectively. Libtayo, a programmed death receptor1 pd1 inhibitor, is the first and only fdaapproved therapy indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma cscc or locally advanced cscc who are not candidates for curative surgery or curative radiation 1. The reconstituted concentration of bortezomib for subcutaneous administration 2. Kyprolis is approved for use in combination with dexamethasone or with lenalidomide plus dexamethasone, which are other medicines used to treat multiple myeloma. Incidence and management of adverse events in patients with. Carfilzomibrituximab desensitization in sensitized heart transplant candidates.
Kyprolis is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Kyprolis is a sterile, white to offwhite lyophilized powder and is available as a singledose 10 mg, 30 mg or 60 mg vial. Carfilzomib had antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. Do not use kyprolis if you are allergic to carfilzomib or any of the other ingredients of this medicine listed in section 6. May 08, 2014 carfilzomib, a selective proteasome inhibitor approved in the usa in 2012, is a single agent for relapsed and refractory multiple myeloma.
Aug 01, 2019 carfilzomib was administered weekly on days 1, 8, and 15 of each 28day cycle as a 30minute infusion prior to daratumumab on days when both were administered. Nov 20, 2019 you must read the package leaflet of all medicines that you take in combination with kyprolis so that you understand the information related to those medicines. Phase 3 arrow study of onceweekly kyprolis carfilzomib. Darzalex is a prescription medicine used to treat adults with multiple myeloma. Tap along the timeline to move to different parts of the audio file. Sep, 2019 carfilzomib kyprolis news and resources for multiple myeloma patients, caregivers, and others interested in carfilzomib and multiple myeloma. Ninlaro ixazomib capsules, for oral use hepatotoxicity. Does carfilzomib have specific characteristics best managed by the nonformulary process, prior authorization, criteria for use. To be empowered to play an active role in your own medical care and to make good decisions about your care with your doctor, it is.
1609 984 772 255 1287 1318 1242 1245 329 1401 287 84 366 1134 1232 1286 180 280 204 1101 244 1469 289 280 10 1160 1411 1302 152 579 1383 1214 678 1361 1071 1140 1058